Archive | Of Interest

Nivolumab Demonstrates Durable Long-term Survival in Patients with Advanced Cancers

Treatment with nivolumab demonstrated durable survival in previously-treated patients with advanced melanoma, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC), according to a new study published in JAMA Oncology.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Personalized Vaccine Shows Protective Benefit Against Disease Recurrence in High-Risk Melanoma

A personalized therapeutic cancer vaccine being developed by Elios Therapeutics for patients with high-risk melanoma demonstrated positive results in a phase 2b clinical trial, according to a press release. 

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Targeted Drug Combination Can Have Long-Lasting Results for Some With BRAF-Mutated Melanoma

A personalized therapeutic cancer vaccine being developed by Elios Therapeutics for patients with high-risk melanoma demonstrated positive results in a phase 2b clinical trial, according to a press release.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Study finds genetic testing motivates behavior changes in families at risk for melanoma

Skin cancer is the most commonly diagnosed cancer in the United States, and melanoma is the most severe type of skin cancer.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest